HONEYWELL HOMMED WINS 2008 MEDICAL DESIGN EXCELLENCE AWARD
Innovative Device Recognized for Design Excellence and Patient Ease-of-Use
Brookfield, WI (April 7, 2008) – Honeywell (NYSE: HON) today won the 2008 Medical Design Excellence Awards (MDEA) for its GenesisTM DM remote patient care device. The Genesis DM won in the rehabilitation and assistive-technology products category.
The award-winning Honeywell HomMed remote patient monitoring device is ideal for both the patient and the medical professional, using text or voice prompts to guide patients through a series of yes/no questions that allow medical professionals to monitor and receive a thorough health assessment.
The Honeywell HomMed remote patient monitoring device is part of the LifeStream Ecosystem and provides patients with an easy-to-use device for the home. The three-part LifeStream ecosystem, providing cost-effective care for patients at home, includes the patient-facing Genesis DM device, software applications and service. Patients suffering from a variety of chronic conditions, such as congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, diabetes and hypertension, can use the Genesis DM device to assess their condition in the privacy of their homes. This information is transmitted securely over the internet to their caregiver for monitoring and the appropriate intervention if necessary.
“When designing the Genesis DM, we listened to the ultimate customer – patients. Without more consistent patient use of telemonitoring, the delivery of telehealth cannot be optimized,” said Mike Benjamin, president of Honeywell HomMed. “We’re honored to receive this recognition and proud of the team at Honeywell HomMed who made this possible. Our focus continues to be ensuring chronically ill patient’s independent living with dignity for at an affordable cost.”
“It is very important to us to provide our patients and caregivers with the most meaningful information with regards to patient health,” said Terry Duesterhoeft, vice president of Marketing & Sales, Honeywell. “As we developed the Genesis DM, we closely evaluated the entire patient environment and discovered that the integration of all data (both objective and subjective) truly differentiated this product in the overall telehealth ecosystem.”
The Medical Design Excellence Awards, now in its eleventh year, recognizes companies and individuals worldwide involved in the design, engineering, manufacture or distribution of finished medical devices or medical packaging. Entries are evaluated by a multidisciplinary panel of jurors with expertise in engineering, medicine, industrial design, manufacturing and other design- and healthcare-related fields.
For more information about Honeywell HomMed’s telehealth solutions, visit www.hommed.com.
Honeywell International is a $36 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell’s shares are traded on the New York, London and Chicago Stock Exchanges. For additional information, please visit www.honeywell.com.
Forward Looking Statement
This release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management’s assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.